{'fraction_non_alphanumeric': 0.016706443914081145, 'fraction_numerical': 0.008353221957040573, 'mean_word_length': 5.606299212598425, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
ORAL DISOPYRAMIDE DOSAGE REGIMES IN ISCHAEMIC HEART DISEASE

The serum concentration/time profiles resulting from two oral disopyramide dosage regimes were studied in ten patients with ischaemic heart disease. Conventional dosing on a 6 or 8 hourly basis consistently achieved disopyramide concentrations within the accepted therapeutic range of 2–7 μg/ml. In contrast, a twice daily regime was associated in some patients with trough levels below the minimum effective concentration. The mean elimination half‐life was 58 h; this does not substantiate previous reports of significantly prolonged disopyramide half‐lives in patients with ischaemic heart disease. Unless significant renal impairment or cardiac failure is present, or a sustained release preparation is used, the dosage interval for oral disopyramide should not exceed 8 h.